Aptevo TherapeuticsAPVO -0.66%29 Market Cap is $5.67 Mil as of Jun. 27, 2026. GuruFocus rates APVO with a GF Score™ of 29/100. The stock has 1 warning sign investors should review. Among 1,431 Biotechnology companies, Aptevo Therapeutics ranks worse than 89.87% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Aptevo Therapeutics's share price for the quarter that ended in Mar. 2026 was $4.27. Aptevo Therapeutics's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 1.20 Mil. Therefore, Aptevo Therapeutics's market cap for the quarter that ended in Mar. 2026 was $5.14 Mil.
Aptevo Therapeutics's quarterly market cap
declined
from Sep. 2025 ($20.02 Mil) to Dec. 2025 ($9.41 Mil) and
declined
from Dec. 2025 ($9.41 Mil) to Mar. 2026 ($5.14 Mil).
Aptevo Therapeutics's annual market cap
increased
from Dec. 2023 ($0.00 Mil) to Dec. 2024 ($6.21 Mil) and
increased
from Dec. 2024 ($6.21 Mil) to Dec. 2025 ($9.41 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Aptevo Therapeutics's Enterprise Value for Today is $-4.43 Mil.
Aptevo Therapeutics (NAS:APVO) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Aptevo Therapeutics Market Cap Related Terms
Aptevo Therapeutics Market Cap Historical Data
* Premium members only.
The historical data trend for Aptevo Therapeutics's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Aptevo Therapeutics's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aptevo Therapeutics Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Aptevo Therapeutics's Market Cap distribution charts can be found below:
* The bar in red indicates where Aptevo Therapeutics's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Aptevo Therapeutics's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aptevo Therapeutics (APVO) has a Market Cap of $5.67 Mil as of Jun. 27, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Aptevo Therapeutics and its competitors. According to the industry distribution chart, Aptevo Therapeutics ranks #1286 out of 1431 companies in the Biotechnology industry, placing it in the top 89.9%.
Is Aptevo Therapeutics' Market Cap too high?
Aptevo Therapeutics' current Market Cap is $5.67 Mil. The Biotechnology industry median Market Cap is 113.83. Aptevo Therapeutics' value of $5.67 Mil is 95% below this industry median. Based on the distribution chart, Aptevo Therapeutics ranks #1286 out of 1431 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Aptevo Therapeutics has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does Aptevo Therapeutics' Market Cap compare to FBLG and BGMS?
According to the Biotechnology industry distribution chart, Aptevo Therapeutics ranks #1286 out of 1431 companies for Market Cap. This places Aptevo Therapeutics in the lower half of its industry. The industry median Market Cap is 113.83. Aptevo Therapeutics' value of $5.67 Mil is 95% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 113.83, based on 1,431 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Aptevo Therapeutics's current Market Cap of $5.67 Mil is 95% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Aptevo Therapeutics and its competitors. For the Biotechnology industry, the median Market Cap is 113.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aptevo Therapeutics's current Market Cap is $5.67 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aptevo Therapeutics stock overvalued right now?
Aptevo Therapeutics (APVO) has a current Market Cap of $5.67 Mil. The current Market Cap is $5.67 Mil and 95% below the Biotechnology industry median of 113.83. Aptevo Therapeutics' overall GF Score™ is 29/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Aptevo Therapeutics (APVO), the current Market Cap is $5.67 Mil as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, CD3xCD123, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.
29GF Score
Get the complete analysis for APVO
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
APVO has been successfully added to your 
